Thursday, 19 Nov 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US

Hairstetics

  • #
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
  • Rare / orphan disease drugs
  • Auto-immune
  • Vaccine
  • Cell-therapy
  • Multi-specific antibodies
  • CVD
  • AstraZeneca
  • Hengrui Pharmaceuticals
  • SHA: 600276
  • Diabetes
Biokin's SystImmune Receives Second USD 250 Million Milestone from BMS for Iza‑Bren – Cumulative Payments Reach USD 1.3 Billion with Up to USD 7.1 Billion Still Contingent
CompanyDeals

Biokin’s SystImmune Receives Second USD 250 Million Milestone from BMS for Iza‑Bren – Cumulative Payments Reach USD 1.3 Billion with Up to USD 7.1 Billion Still Contingent

Biokin Pharmaceutical (SHA: 688506) announced that its wholly‑owned subsidiary SystImmune has received a second milestone payment of USD 250 million from Bristol-Myers Squibb (BMS) (NYSE: BMY) under their collaboration on…

November 18, 2026
Phrontline Biopharma Raises Nearly USD 40 Million Series A – Capitalizing First‑in‑Class Bispecific ADC Program as TJ101 and TJ102 Advance in the Clinic

Phrontline Biopharma Raises Nearly USD 40 Million Series A – Capitalizing First‑in‑Class Bispecific ADC Program as TJ101 and TJ102 Advance in the Clinic

November 18, 2026
Philips Health and Shanghai Sixth People's Hospital Sign Strategic Cooperation MoU – Joint Medical Imaging Laboratory to Advance Multinuclear MRI and Large Medical AI Models

Philips Health and Shanghai Sixth People’s Hospital Sign Strategic Cooperation MoU – Joint Medical Imaging Laboratory to Advance Multinuclear MRI and Large Medical AI Models

November 18, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyMedical Device

Israeli Hair Transplant Innovator Hairstetics Launches First Procedure in Asia at Hainan Hospital

October 12, 2024
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up